Amarillo Biosciences and Oasis Diagnostics have entered into an agreement for Oasis to exclusively market Maxisal, Amarillo Biosciences' dietary supplement for enhancing salivary function, promoting oral comfort, and relieving dry mouth, in North, Central, and South America; China; and Taiwan.
Oasis, a salivary diagnostics and genomics company, plans to expand on Amarillo's current marketing efforts by exploring new potential markets for Maxisal in patients undergoing kidney dialysis and chemotherapy, those with dryness-related sexual dysfunction, and individuals with burning mouth syndrome and other dryness-related conditions.
Maxisal is currently marketed by Amarillo's licensees Egofocus in Germany and Zydus Cadila in India. The first target market in Germany and India is cancer patients. There are more than 400 medications, including some oncology drugs that cause dry mouth as a severe side effect; by taking Maxisal, cancer patients may be able to relieve at least one of the unpleasant side effects associated with cancer therapy, the companies noted.
Maxisal was first offered for sale in the U.S. after clinical studies in subjects with Sjögren's syndrome reported that the active ingredient in Maxisal significantly improved mouth comfort and decreased mouth and throat dryness, the companies said.
Copyright © 2011 DrBicuspid.com
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
